Saniona AB (publ) (STO:SANION)

Market Cap	3.40B +377.4%
Revenue (ttm)	743.21M +2,687.5%
Net Income	573.47M
EPS	4.56
Shares Out	138.03M
PE Ratio	5.40
Forward PE	10.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	456,138
Average Volume	841,759
Open	24.60
Previous Close	24.60
Day's Range	24.45 - 25.75
52-Week Range	5.41 - 28.30
Beta	1.39
RSI	53.18
Earnings Date	Feb 26, 2026

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 31
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SANION